SEP 02, 2019 1:43 PM PDT

Standard Treatment Resistance Discovered in Crohn's Disease

WRITTEN BY: Nouran Amin

Researchers have mapped out more than 100,000 immune cells from biopsy samples of patients with Crohn's disease. The biopsy samples were retrieved from regions of inflamed and uninflamed Crohn's disease lesions on small intestine tissue and the analysis indicated a signature of cells implicated in the disease that does not respond to treatment. The discovery provides new clues to how we approach novel therapeutic options—findings were published in Cell.

Learn more about Crohn’s Disease:

"We designed this study in a way that defines inflammation with unprecedented precision using immunology and computational biology to get a better understanding of this disease," said co- corresponding author Judy H. Cho, MD, Senior Associate Dean for Precision Medicine, Director of The Charles Bronfman Institute for Personalized Medicine, Ward-Coleman Professor of Translational Genetics, and Professor of Medicine, and Genetics and Genomic Sciences, at the Icahn School of Medicine. "These results emphasize the limitations of current diagnostic assays and the potential for single-cell mapping tools to identify novel biomarkers for treatment response and tailored therapeutic opportunities."

After using techniques such as single-cell RNA sequencing and CyTOF technology, researchers identified for the first time a precise cell type resistant to the standard therapy for Crohn's disease, an anti-inflammatory drug called a TNF inhibitor. The drug is a major agent delivered to patients with moderate to severe Crohn's disease, however, roughly 40 percent of these patients taking the inhibitor do not respond to the therapy.

"Single-cell profiling could transform drug discovery," said co-corresponding author Miriam Merad, MD, PhD, Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai, Mount Sinai Professor in Cancer Immunology, Co-Director of the Cancer Immunology Program at The Tisch Cancer Institute and Director of the Mount Sinai Human Immune Monitoring Center. "It's really going to give us much more clarity into inflammatory bowel disease and why patients are resisting and what else we could be targeting."

Discovering a signature of cells can help identify patients who fail on this therapeutic inhibitor and avoid surgical complications. The study has allowed researchers to explore new ways of developing diagnostic methods that can determine such signature through a simple blood test. If such a diagnostic method is developed, doctors can prescribe other medicines besides a TNF inhibitor that will work well for their patients.

"Our study shows that approaches that combine high-resolution single-cell mapping of inflammatory lesions in small numbers of patients with bulk RNA sequencing on large cohorts with extensive clinical characterization leads to generalizable insights, highlighting the potential to broadly transform understanding of human multifactorial immune-mediated inflammatory diseases," said co-corresponding author Ephraim Kenigsberg, PhD, Assistant Professor of Genetics and Genomic Sciences at the Icahn Institute for Data Science and Genomic Technology.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 22, 2020
Drug Discovery & Development
Evaluating a Popular Diabetic Drug
MAY 22, 2020
Evaluating a Popular Diabetic Drug
A study by researchers at UT Southwestern study shows that a previous drug for Type 2 diabetes may be effective when pai ...
MAY 28, 2020
Drug Discovery & Development
Trial for Arthritis Drug with Remdesivir to Beat COVID-19
MAY 28, 2020
Trial for Arthritis Drug with Remdesivir to Beat COVID-19
Montefiore Health System and Albert Einstein College of Medicine in New York have teamed up to see how well remdesivir, ...
JUN 07, 2020
Cannabis Sciences
Should You Smoke Cannabis Seeds and Stems?
JUN 07, 2020
Should You Smoke Cannabis Seeds and Stems?
When smoking cannabis, people typically use either the flower, buds, or leaves. But what about the seeds and stems? Can ...
JUN 10, 2020
Drug Discovery & Development
A Highly Targeted Cancer Therapeutic
JUN 10, 2020
A Highly Targeted Cancer Therapeutic
A study led by researchers at USC School of Pharmacy discusses a way to engineer drugs that highly target malignant tiss ...
JUN 22, 2020
Drug Discovery & Development
New Drug Shows Promise in Fatty Liver Disease
JUN 22, 2020
New Drug Shows Promise in Fatty Liver Disease
A scientist leads a team to discover the first-of-its-class drug that can inhibit a key enzyme safely and effectively in ...
JUL 02, 2020
Cannabis Sciences
What is the Difference Between CBD and CBG?
JUL 02, 2020
What is the Difference Between CBD and CBG?
Like cannabidiol (CBD), cannabigerol (CBG) is a cannabinoid. Both compounds are found in cannabis plants. Both are also ...
Loading Comments...